• Connect with us
  • Information
    • About Us
    • Contact Us
    • Careers
    • Partnerships
    • Advertise With Us
    • Authors
    • Browse Topics
    • Events
    • Disclaimer
    • Privacy Policy
  • NORTH AMERICA EDITION
    Australia
    North America
    World
Login
Investing News NetworkYour trusted source for investing success
  • NORTH AMERICA EDITION
    North America
    Australia
    World
  • My INN
Videos
Companies
Press Releases
Private Placements
SUBSCRIBE
  • Reports & Guides
    • Market Outlook Reports
    • Investing Guides
  • Button
Resource
  • Precious Metals
  • Battery Metals
  • Base Metals
  • Energy
  • Critical Minerals
Tech
Life Science
Life Science Market
Life Science News
Life Science Stocks
  • Life Science Market
  • Life Science News
  • Life Science Stocks

2014 a Bad Year for Public Health; 2015 Unlikely to Differ

Charlotte McLeod
Dec. 19, 2014 08:50AM PST
Life Science Investing

The Associated Press reported that 2014 was a “black-eye year for public health” due to a variety of mishaps, including “vital vaccines” failing to work and the worst-ever Ebola epidemic.

The Associated Press reported that 2014 was a “black-eye year for public health” due to a variety of mishaps, including “vital vaccines” failing to work and the worst-ever Ebola epidemic. And while there were some success stories, some believe the future doesn’t look particularly bright.

As quoted in the market news:

Infectious diseases are a continuing threat, and no one should think of 2014 as an aberration, said Michael Osterholm, a University of Minnesota infectious disease expert.

‘I think what we really hit is a new normal,’ he said.

Indeed, it could get worse. Osterholm noted that Ebola and MERS barely touched the U.S. this year, and worrisome forms of influenza in Asia and elsewhere may be on the horizon. Arrivals of people from overseas — and whatever germs they’re carrying — are forecast to keep growing. And adding to the threat of new bugs is the revived menace from old ones, as once-treatable germs are increasingly becoming resistant to antibiotics, experts said.

Click here to read the full report from the Associated Press.

life-science-investing infectious-disease
The Conversation (0)

Go Deeper

AI Powered
Scientist pouring blue liquid from a test tube into a flask in a lab.

Biotech Market Forecast: Top Trends for Biotech in 2026

Various colorful pills and tablets scattered from a brown bottle on a blue background.

Pharma Market Forecast: Top Trends for Pharma in 2026

Latest News

Cardiol Therapeutics' ARCHER Phase II Study Results Published in ESC Heart Failure

More News

Outlook Reports

Resource
  • Precious Metals
    • Gold
    • Silver
  • Battery Metals
    • Lithium
    • Cobalt
    • Graphite
    • Electric Vehicles
  • Agriculture
  • Base Metals
    • Copper
    • Nickel
    • Zinc
  • Critical Metals
    • Rare Earths
  • Energy
    • Uranium
    • Oil and Gas
Tech
    • Artificial Intelligence
    • Cybersecurity
    • Robotics
    • Crypto
    • Cleantech
Life Science
    • Biotech
    • Cannabis
    • Pharmaceuticals

Featured Life Science Investing Stocks

More featured stocks

Browse Companies

Resource
  • Precious Metals
  • Battery Metals
  • Energy
  • Base Metals
  • Critical Metals
Tech
Life Science
MARKETS
COMMODITIES
CURRENCIES